# Control of cell payloads by endogenous promoters

Source: https://onco.cc/terms/endogenous-promoter-payload-control/  
OnCo record `endogenous-promoter-payload-control` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An engineered cell can place a payload under the control of a naturally regulated gene. The resulting expression pattern still needs measurement in the actual cells and tissues.

## Summary

A CRISPR knock-in can connect an engineered cytokine payload to regulatory control at an endogenous gene locus. In preclinical work, NR4A2 and RGS16 control supported cytokine expression in specified CAR T-cell settings, with tumor and safety measurements in mouse models. This is distinct from adding synthetic response elements to a separate promoter. Neither the locus name nor an activation-responsive design proves tumor-only secretion, clinical safety or patient benefit.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: NR4A2 cytokine payload control; RGS16 cytokine payload control; activation-responsive cytokine expression

## Notes

- Chen and colleagues screened endogenous genes and investigated NR4A2/RGS16 regulation for payloads including IL-12 and IL-2 in cell and mouse models. Patient-derived cells were also studied experimentally; that is not a clinical treatment result in those patients. The edited locus, retained native gene function, off-state expression, inducibility and persistence need characterization.
- Guo and colleagues instead tested a synthetic NR4A-responsive promoter against a conventional NFAT-responsive promoter in human-cell experiments with weak stimulation. Reporter expression and improved proliferation in that system do not establish a clinical potency or safety ranking, and the synthetic promoter is distinct from an endogenous NR4A2-locus knock-in.
- Keep trigger recognition, payload transcription, secretion, tissue distribution and downstream activity separate. The IL-12 TIL clinical experience shows why inducible production alone cannot establish confinement or freedom from systemic toxicity. Viable producer-cell abundance, time and cell state matter alongside cytokine concentration.

## Sources

- Chen et al.: endogenous-locus control of cytokine payloads in preclinical models (2025): https://pubmed.ncbi.nlm.nih.gov/40604285/
- Guo et al.: synthetic NR4A-responsive payload promoter in human-cell experiments (2022): https://pubmed.ncbi.nlm.nih.gov/35316028/
- Zhang et al.: inducible IL-12 TIL study and systemic toxicity (2015): https://pubmed.ncbi.nlm.nih.gov/25695689/

## Connected records

- technologies: [Armoured, logic-gated & next-gen CARs](https://onco.cc/technologies/armored-car/)
- terms: [Cellular kinetics and persistence](https://onco.cc/terms/cellular-kinetics-and-persistence/), [Promoters, enhancers and transcription factors](https://onco.cc/terms/gene-regulatory-elements/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/endogenous-promoter-payload-control.json